Edition:
United Kingdom

Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

42.64CHF
23 May 2019
Change (% chg)

-- (--)
Prev Close
CHF42.64
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
45,447
52-wk High
CHF73.40
52-wk Low
CHF38.60

Latest Key Developments (Source: Significant Developments)

Basilea Pharmaceutica FY Net Loss Widens To CHF 31.4 Million
Tuesday, 19 Feb 2019 

Feb 19 (Reuters) - Basilea Pharmaceutica AG ::BASILEA REPORTS STRONG REVENUE GROWTH AND SIGNIFICANT PIPELINE PROGRESS FOR FULL-YEAR 2018.FY TOTAL REVENUE INCREASED 31% TO CHF 133 MILLION.FY REVENUE FROM CRESEMBA(®) AND ZEVTERA(®) INCREASED 56% TO CHF 82 MILLION.YEAR-END CASH POSITION OF CHF 223 MILLION.OPERATING LOSS IN 2018 AMOUNTED TO CHF 24.1 MILLION (2017: CHF 17.1 MILLION).ANTICIPATES 2019 CONTINUED STRONG REVENUE GROWTH FROM CRESEMBA AND ZEVTERA TO CHF 100-110 MILLION (+22-34% Y-ON-Y).FY NET LOSS CHF 31.4 MILLION VERSUS LOSS CHF 19.4 MILLION YEAR AGO.2019 TOTAL OPERATING EXPENSES ARE EXPECTED TO REMAIN AT APPROXIMATELY SAME LEVEL AS 2018,.SEES FY 2019 OPERATING LOSS OF CHF 20-30 MILLION FOR 2019.SEES 2019 TOTAL REVENUES TO AMOUNT TO CHF 128-138 MILLION.  Full Article

Basilea Preliminary FY Revenue At CHF 133 Mln
Monday, 7 Jan 2019 

Jan 7 (Reuters) - BASILEA PHARMACEUTICA AG ::BASILEA REPORTS STRONG, HIGHER THAN EXPECTED PRELIMINARY REVENUE OF CHF 133 MILLION FOR FINANCIAL YEAR 2018.FY TOTAL REVENUE IS EXPECTED TO INCREASE BY 31% OVER 2017 TO APPROX. CHF 133 MILLION (FYR 2017: CHF 101.5 MILLION).  Full Article

Basilea Pharmaceutica Appoints Gerrit Hauck As CTO
Friday, 27 Apr 2018 

April 27 (Reuters) - BASILEA PHARMACEUTICA AG ::GERRIT HAUCK APPOINTED AS CHIEF TECHNOLOGY OFFICER.  Full Article

Basilea Pharmaceutica FY Operating Loss At CHF 14.1 million
Tuesday, 27 Feb 2018 

Feb 27 (Reuters) - BASILEA PHARMACEUTICA AG ::FY ‍54% INCREASE IN TOTAL REVENUE, AMOUNTING TO CHF 101.5 MILLION​.FY OPERATING LOSS REDUCED BY 68% TO CHF 14.1 MILLION.‍CASH POSITION AS OF YEAR-END 2017 INCREASED TO CHF 310.7 MILLION​.‍NET LOSS IN 2017 WAS REDUCED TO CHF 19.4 MILLION (2016: CHF 51.3 MILLION)​.OUTLOOK 2018: ANTICIPATES TOTAL REVENUE OF APPROXIMATELY CHF 105-115 MILLION.OPERATING LOSS IN 2018 IS ESTIMATED AT APPROXIMATELY CHF 10-20 MILLION.  Full Article

Basilea Appoints David Veitch As New CEO
Wednesday, 21 Feb 2018 

Feb 21 (Reuters) - BASILEA PHARMACEUTICA AG ::BASILEA'S CEO RONALD SCOTT WILL RETIRE. CHIEF COMMERCIAL OFFICER DAVID VEITCH NAMED AS SUCCESSOR. CHANGES IN THE BOARD OF DIRECTORS.DAVID VEITCH TO SUCCEED MR. SCOTT IN ROLE OF CHIEF EXECUTIVE OFFICER EFFECTIVE APRIL 19, 2018.  Full Article

Basilea Announces Completion Of License Agreement Extension With Pfizer
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Basilea Pharmaceutica AG ::BASILEA ANNOUNCES COMPLETION OF THE LICENSE AGREEMENT EXTENSION WITH PFIZER FOR ANTIFUNGAL CRESEMBA FOR CHINA AND ASIA PACIFIC.  Full Article

Basilea starts clinical phase 1 study in collaboration with U.S. Adult Brain Tumor Consortium ​
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Basilea Pharmaceutica Ag ::‍INITIATION OF A PHASE 1 STUDY CONDUCTED UNDER ITS CLINICAL STUDY AGREEMENT WITH ADULT BRAIN TUMOR CONSORTIUM IN U.S.​.‍BASILEA EXPECTS TO COMPLETE PHASE 1 PATIENT RECRUITMENT INTO SEPARATE GLIOBLASTOMA ARM OF ORAL STUDY IN FIRST HALF OF 2018​.  Full Article

Basilea: Ceftobiprole Gets QIDP Designation From U.S. FDA
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - BASILEA PHARMACEUTICA AG ::BASILEA REPORTS THAT CEFTOBIPROLE RECEIVED QIDP DESIGNATION FROM U.S. FDA FOR THE TREATMENT OF STAPHYLOCOCCUS AUREUS BACTEREMIA (SAB).  Full Article

Basilea Extends Existing License Agreement With Pfizer For Cresemba
Friday, 1 Dec 2017 

Dec 1 (Reuters) - BASILEA PHARMACEUTICA AG ::BASILEA EXTENDS EXISTING LICENSE AGREEMENT WITH PFIZER <<>> FOR ANTIFUNGAL CRESEMBA® (ISAVUCONAZOLE) TO CHINA AND ASIA PACIFIC.BASILEA UPDATES ITS FINANCIAL GUIDANCE FOR 2017 - IMPROVED RESULT EXPECTED.ELIGIBLE TO RECEIVE MILESTONE PAYMENTS OF UP TO USD 226 MILLION AND MID-TEEN ROYALTIES ON SALES.WILL RECEIVE UPFRONT PAYMENT OF USD 3 MILLION.FOR FY EXPECTS A REDUCED OPERATING LOSS OF APPROXIMATELY CHF 1 MILLION ON AVERAGE PER MONTH.FOR FY SEES LOWER OPERATING EXPENSES.  Full Article

Basilea Pharmaceutica ‍marketing authorization for Cresemba for Switzerland​
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - BASILEA PHARMACEUTICA AG ::‍MARKETING AUTHORIZATION RECEIVED FOR CRESEMBA FOR SWITZERLAND​.  Full Article

Swiss stocks - Factors to watch on May 2

ZURICH/BERLIN, May 2 The Swiss blue-chip SMI was seen opening 0.2 percent lower at 9,748 points on Thursday, according to premarket indications by bank Julius Baer .